Mumbai: Global pharma major Lupin Limited has announced the acquisition of Huminsulin in India from Eli Lilly and Company to further enhance its diabetes portfolio. Lupin has been marketing

Lupin Ltd. acquires Huminsulin range from Eli Lilly, strengthening its position in the Indian diabetes market.

The stock of the pharmaceutical company, Lupin is quoting higher for the sixth straight trading day; it has rallied 10 per cent during the period

Lupin has acquired 'Huminsulin' in India from Eli Lilly and Company to strengthen its diabetes portfolio. The acquisition aims to provide affordable and accessible insulin treatment for patients with Type 1 and Type 2 diabetes.